Biotinylated Human Fc gamma RIIIA / CD16a (F176) Protein, Avitag?,His Tag (SPR & BLI & MALS verified)
分子別名（Synonym）
FCGR3A, CD16A, FCG3, FCGR3, IGFR3
表達(dá)區(qū)間及表達(dá)系統(tǒng)（Source）
Biotinylated Human CD16a (F176), Avitag,His Tag (CDA-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Gln 208 (Accession # P08637-1).
Predicted N-terminus: Gly 17
蛋白結(jié)構(gòu)（Molecular Characterization）
This protein carries an Avi tag (Avitag?) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 25.5 kDa. The protein migrates as 40-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記（Labeling）
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
純度（Purity）
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 12 months under sterile conditions after reconstitution.
背景介紹
CD16作為低親和力Fc受體，包含FcγRIIIa（CD16a）與FcγRIIIb（CD16b）兩種亞型，二者均特異性結(jié)合IgG抗體的Fc段并由高度同源基因以細(xì)胞類型特異性方式編碼，表達(dá)于自然殺傷細(xì)胞、中性粒細(xì)胞、單核細(xì)胞及巨噬細(xì)胞表面。其中CD16a（低親和力免疫球蛋白γ Fc段受體III-A）作為中親和力跨膜糖蛋白（多肽錨定），分布于NK細(xì)胞、巨噬細(xì)胞、T細(xì)胞亞群、未成熟胸腺細(xì)胞及胎盤滋養(yǎng)層細(xì)胞，介導(dǎo)吞噬作用、酶類與炎癥介質(zhì)分泌、抗體依賴性細(xì)胞毒性及免疫復(fù)合物清除；而CD16b則是中性粒細(xì)胞和嗜酸性粒細(xì)胞表達(dá)的低親和力GPI錨定受體。CD16a的功能異常與復(fù)發(fā)性病毒感染易感性、系統(tǒng)性紅斑狼瘡及同種免疫性新生兒中性粒細(xì)胞減少癥密切相關(guān)。
關(guān)鍵字： Fc gamma RIIIA;FCGR3A蛋白;CD16A重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。